Stocks to Watch For: The Boeing Company (BA), Sucampo Pharmaceuticals, Inc. (SCMP)

Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its earnings results on Wednesday, November 9th.

For the current quarter, 6 analysts are projecting a mean EPS of $0.35/share. It is positive, as 14 investors sold Sucampo Pharmaceuticals, Inc. shares while 40 reduced holdings.

According to 5 analysts, the Average Revenue Estimate for the current Fiscal quarter is $896.88 Million and the Low Revenue estimate is $835 Million, while the High Revenue estimate is $957.1 Million. The stock decreased 0.14% or $0.02 during the last trading session, reaching $18.38. Advisor Group Inc. raised its position in Sucampo Pharmaceuticals by 45.1% in the 3rd quarter.

A number of other brokerages have also recently weighed in on SCMP. The stock appeared $18.75 above its 52-week highs and is up 3.62% for the last five trades. The rating was downgraded by Maxim Group on Tuesday, December 26 to "Hold".

Sucampo Pharmaceuticals, Inc. (SCMP) analysts on average have given a price target of $25.15 on SCMP stock. Nomura began coverage on Sucampo Pharmaceuticals in a research report on Monday, December 18th. They issued a "buy" rating and a $14.00 price objective for the company. Six research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Sucampo Pharmaceuticals now has a consensus rating of "Buy" and an average price target of $17.33. Sucampo Pharmaceuticals, Inc. (SCMP) has 0 billion shares outstanding now, 64.96% of which belong to institutional investors. 1,562,916 shares of the stock were exchanged, compared to its average volume of 4,243,397. The Firm has ATR of 0.63 that is explaining range of a day's trading is high-low; ATR expands it to yesterday's closing price if it was outside of latest range. Stocks with a beta above 1 are more volatile than the market as a whole. Nine Chapters Capital Management LLC bought a new stake in Sucampo Pharmaceuticals in the third quarter valued at about $127,000. Krensavage Asset Management LLC now owns 2,819,708 shares of the biopharmaceutical company's stock valued at $29,607,000 after purchasing an additional 16,570 shares in the last quarter. In the most recent quarterly financial report, for the quarter ending Sep. The firm owned 20,213 shares of the biopharmaceutical company's stock after selling 1,299 shares during the period. The average investment recommendation for SCMP, taken from a group of Wall Street Analysts, is 2.70, or a hold. Trexquant Investment LP purchased a new stake in shares of Sucampo Pharmaceuticals in the third quarter valued at $122,000. Prudential Financial Inc. now owns 410,323 shares of the biopharmaceutical company's stock worth $4,842,000 after purchasing an additional 368,090 shares during the last quarter.

In related news, insider Peter A. Kiener sold 50,000 shares of Sucampo Pharmaceuticals stock in a transaction on Thursday, December 7th. The share price has moved forward from its 20 days moving average, trading at a distance of 7.43% and stays 37.32% away from its 50 days moving average. Insiders own 4.13% of the company's stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

ILLEGAL ACTIVITY WARNING: This story was originally posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and global copyright and trademark law.

Analysts await Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. The companyÂ's marketed product includes AMITIZA, a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC) in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension.